美迪凱(688079.SH):擬使用募集資金2億元向美迪凱光學半導體增資 用於光學光電子元器件生產基地建設項目
格隆匯3月8日丨美迪凱(688079.SH)公佈,2022年3月8日,公司第一屆董事會第二十一次會議和第一屆監事會第十二次會議審議通過了《關於使用部分募集資金向全資子公司進行增資以實施募投項目的議案》,同意公司使用募集資金人民幣2億元向全資子公司美迪凱光學半導體增資,用於光學光電子元器件生產基地建設項目。此次增資,美迪凱光學半導體將新增註冊資本2億元,增資完成後,美迪凱光學半導體註冊資本由7.08億元增至9.08億元。公司仍持有美迪凱光學半導體100%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.